Laurel, MD, December 11, 2006 – BioServe, a leading provider of rapid, economical processing and analyses of genomic content from biological samples, today introduced its new DNA Methylation Analysis Service using Sequenom, Inc.’s (Nasdaq: SQNM) MassARRAY® System and EpiTYPERTM™ methodology. DNA methylation markers are a new and important class of biomarkers that are significant because of their correlation to gene activity. High levels of cytosine methylation in genomic regions (CpG islands) are often associated with decreased or completely inhibited gene expression. Researchers now believe that DNA methylation patterns play an important role in early cancer detection and prognosis. BioServe’s Methylation Analysis Service will aid researchers’ understanding of methylation patterns with quantitative results in the form of methylation ratios in targeted genomic regions.
“DNA methylation patterns affect phenotype and cell biology, as most obviously seen in cancers. Understanding this epigenetic dysregulation is essential to potentially mediating many common diseases. “BioServe’s new Methylation Analysis Service will aid researchers studying a variety of diseases identify CpG disturbances in the genome and gain new insights into the roots of disease,” said Rama Modali, President of BioServe. “For example, our Methylation Service gives researchers the ability to efficiently measure methylation activity at individual sites in the genome and quantitatively measure methylation ratios across multiple methylation sites over multiple samples.”
Sequenom(R), MassARRAY(R), EpiTYPER(TM), and iPLEX(TM) are trademarks of Sequenom, Inc.